Basics Kyverna Therapeutics, Inc. Common Stock IPO Date: February 9, 2024 Sector: Healthcare Industry: Biotech Market Cap: $341.61M Activated in VL: True Average Daily Range Avg Daily Range: $0.34 | 4.51% Avg Daily Range (30 D): $0.41 | 5.85% Avg Daily Range (90 D): $0.29 | 4.99% Institutional Daily Volume Avg Daily Volume: .38M Avg Daily Volume (30 D): .63M Avg Daily Volume (90 D): .51M Trade Size Avg Trade Size (Sh.): 98 Avg Trade Size (Sh.) (30 D): 97 Avg Trade Size (Sh.) (90 D): 102 Institutional Trades Total Inst.Trades: 117 Avg Inst. Trade: $1.96M Avg Inst. Trade (30 D): $6M Avg Inst. Trade (90 D): $3.33M Avg Inst. Trade Volume: .18M Avg Inst. Trades (Per Day): 1 Market Closing Trades Avg Closing Trade: $2.79M Avg Closing Trade (30 D): $6.42M Avg Closing Trade (90 D): $6.42M Avg Closing Volume: 272.03K     News Oct 6, 2025 @ 5:00 PM Diffuse Cutaneous Systemic Sclerosis Market Foreca... Source: Delveinsight Aug 28, 2025 @ 12:00 PM Kyverna Therapeutics Highlights Neuroimmunology CA... Source: Kyverna Therapeutics Mar 18, 2025 @ 8:48 PM Notice to Long-Term Shareholders of Archer-Daniels... Source: Grabar Law Office Mar 13, 2025 @ 10:21 PM Long-Term Shareholder Notice: Fluence Energy, Inc.... Source: Grabar Law Office Mar 5, 2025 @ 6:00 PM CAR T-cell Therapy Clinical Trial Pipeline Experie... Source: Delveinsight Financials   TTM Q3 2025 Q2 2025 Basic EPS $-3.73 $-.85 $-.97 Diluted EPS $-3.73 $-.85 $-.97 Revenue $ M $ M $ M Gross Profit $ $ $ Net Income / Loss $ -160.99M $ -36.79M $ -42.08M Operating Income / Loss $ -171.59M $ -38.73M $ -44.41M Cost of Revenue $ $ $ Net Cash Flow $ -70.51M $ -19.28M $ -3.43M PE Ratio